Project Grant K08CA308869
Award Date 9/1/26
Completion Date 8/31/31
Dollars Obligated $225K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute on Aging awarded The General Hospital Corporation (Massachusetts General Hospital) $1,538,587 under the Aging Research program (CFDA 93.866) on February 15, 2026, to conduct a multi-site clinical trial of the COMA Family Program, a resilience intervention for caregivers of patients with severe acute brain injury. The COMA-F intervention delivers six weekly remote video sessions of 30–45 minutes each, designed to teach caregivers coping skills and mindfulness to manage...
- The National Institute of Mental Health awarded The General Hospital Corporation (Massachusetts General Hospital) $765,876 on August 1, 2026, under the Mental Health Research Grants program (CFDA 93.242) to conduct advanced neuroimaging research on subcortical brain dynamics during human sleep. The recipient will use high-resolution 7-Tesla functional magnetic resonance imaging and simultaneous electroencephalography with a novel ultra-high-field compatible net to map circuit activity in the...
- The National Cancer Institute awarded Regents of the University of Michigan $785,278 on August 14, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and evaluate the efficacy of the MI Sleep Coach App, a mobile cognitive behavioral therapy for insomnia (CBT-I) intervention designed specifically for cancer survivors. Sleep disturbances affect over 50 percent of breast, prostate, and colorectal cancer survivors and are associated with negative effects on physical and...
- The National Cancer Institute awarded Wayne State University $398,544 on August 14, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to build and test a clinic-based sleep care pathway for oncology patients with sleep disorders. The project, titled ONC-SLEEP COLLABORATIVE: COMISA COLLABORATIVE CARE INTEGRATION IN ONCOLOGY, addresses comorbid insomnia and obstructive sleep apnea (COMISA) in cancer patients through a team-based collaborative care model. Aim 1...
- The National Institute on Aging awarded $1.9 million to The General Hospital Corporation (Massachusetts General Hospital) on March 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a multisite longitudinal cohort study examining sleep and circadian rhythm biomarkers in postoperative delirium and neurocognitive recovery. The study, titled Sleep and Circadian Rhythm Biomarkers of Postoperative Neurocognitive Recovery (SLEEP-POD2), will enroll 400 adults over age 65 undergoing...
- The National Cancer Institute awarded Massachusetts General Hospital $1.611 million on September 12, 2025, under Cancer Treatment Research (CFDA 93.395) to conduct a randomized controlled trial testing the efficacy of SMART3RP-Lymphoma, a virtual, resilience-based group intervention, in improving quality of life and reducing anxiety, depression, and physical symptoms among early post-treatment lymphoma survivors (0–2 years after curative-intent treatment). The study enrolls 254 participants...
- The National Heart, Lung, and Blood Institute awarded Massachusetts General Hospital (The General Hospital Corporation) $185,196 on January 7, 2027 under the Cardiovascular Diseases Research program (CFDA 93.837). The award funds a pilot multi-center cohort study examining patient and caregiver burden in chronic limb-threatening ischemia (CLTI). Aim 1 will assess how caregiver support relates to patient outcomes including quality of life, amputation, readmission, and mortality, collecting...
- The National Cancer Institute awarded The General Hospital Corporation (Massachusetts General Hospital) $684,857 on September 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a randomized controlled trial expanding the BRIDGE intervention—a person-centered collaborative care model designed to improve cancer care delivery and outcomes for individuals with serious mental illness. The award funds a five-year project (September 1, 2026 through August 31, 2031)...
- The National Cancer Institute, a component of the Department of Health and Human Services, awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $588,606 on August 1, 2026, under the Cancer Cause and Prevention Research program (CFDA 93.393) to conduct a multisite randomized efficacy trial of STRIDE, an evidence-based telehealth intervention for improving symptom management and medication adherence in patients with hormone-sensitive breast cancer receiving...
- The National Institute on Aging awarded Emory University $1,370,546 on February 15, 2026, under the Aging Research program (CFDA 93.866) to conduct a randomized controlled trial testing cognitive behavioral therapy for insomnia (CBT-I) delivered to dyads of persons living with dementia and their caregivers. The study, titled "Testing Cognitive Behavioral Therapy for Insomnia (CBT-I) on Dyadic Sleep in Dementia: A Randomized Control Trial," will enroll 120 dyads and compare the efficacy...